Aarhus University Seal / Aarhus Universitets segl

Christina C. Dahm

Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Konstantinos K Tsilidis
  • ,
  • Naomi E Allen
  • ,
  • Timothy J Key
  • ,
  • Laure Dossus
  • ,
  • Rudolf Kaaks
  • ,
  • Kjersti Bakken
  • ,
  • Eiliv Lund
  • ,
  • Agnès Fournier
  • ,
  • Christina C Dahm
  • Kim Overvad
  • Louise Hansen
  • ,
  • Anne Tjønneland
  • ,
  • Sabina Rinaldi
  • ,
  • Isabelle Romieu
  • ,
  • Marie-Christine Boutron-Ruault
  • ,
  • Francoise Clavel-Chapelon
  • ,
  • Annekatrin Lukanova
  • ,
  • Heiner Boeing
  • ,
  • Madlen Schütze
  • ,
  • Vassiliki Benetou
  • ,
  • Domenico Palli
  • ,
  • Franco Berrino
  • ,
  • Rocco Galasso
  • ,
  • Rosario Tumino
  • ,
  • Carlotta Sacerdote
  • ,
  • H Bas Bueno-de-Mesquita
  • ,
  • Fränzel J B van Duijnhoven
  • ,
  • Marieke G M Braem
  • ,
  • N Charlotte Onland-Moret
  • ,
  • Inger T Gram
  • ,
  • Laudina Rodríguez
  • ,
  • Eric J Duell
  • ,
  • María-José Sánchez
  • ,
  • José María Huerta
  • ,
  • Eva Ardanaz
  • ,
  • Pilar Amiano
  • ,
  • Kay-Tee Khaw
  • ,
  • Nick Wareham
  • ,
  • Elio Riboli
  • Institute of Epidemiology and Social Medicine
  • Kardiologisk Afdeling, Aalborg Sygehus
The association between menopausal hormone therapy (HT) and risk of ovarian cancer was assessed among 126,920 post-menopausal women recruited into the European Prospective Investigation into Cancer and Nutrition. After an average of 9-year follow-up, 424 incident ovarian cancers were diagnosed. Cox models adjusted for body mass index, smoking status, unilateral ovariectomy, simple hysterectomy, age at menarche, number of full-term pregnancies, and duration of oral contraceptives were used. Compared with baseline never use, current use of any HT was positively associated with risk (HR [hazard ratio], 1.29; 95% CI [confidence interval], 1.01-1.65), while former use was not (HR, 0.96; 95% CI, 0.70-1.30). Current estrogen-only HT was associated with a 63% higher risk (HR, 1.63; 95% CI, 1.08-2.47), while current estrogen plus progestin was associated with a smaller and non-significant higher risk (HR, 1.20; 95% CI, 0.89-1.62). Use of tibolone was associated with a twofold greater risk (HR, 2.19; 95% CI, 1.06-4.50), but was based on small numbers. In conclusion, women who currently use HT have a moderate increased risk of ovarian cancer, and which may be stronger for estrogen-only than estrogen plus progestin preparations.
Original languageEnglish
JournalCancer Causes & Control
Volume22
Issue8
Pages (from-to)1075-84
ISSN0957-5243
DOIs
Publication statusPublished - Aug 2011

See relations at Aarhus University Citationformats

ID: 37668242